ArticleAnnual review of cancer biology2023
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy.
Article in Annual review of cancer biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- Structural basis for T-cell receptor recognition of p53Acta crystallographica. Section D, Structural biology · 2026Article
- T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.The Journal of clinical investigation · 2026Article
- Article
- Safety-first TCR-T: AI-guided specificity, base-editing to prevent mispairing, and prioritizing public neoantigens.Frontiers in immunology · 2026Article
- Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.Oncoimmunology · 2025Article
- Review
- Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASJournal for immunotherapy of cancer · 2025Article
- Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials.Journal for immunotherapy of cancer · 2025Review
- Review
- Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.Journal for immunotherapy of cancer · 2025Article
- Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Identification of novel KRASJournal of translational medicine · 2025Article
- Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy.International journal of medical sciences · 2025Review
- T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H.Frontiers in immunology · 2025Article
- Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens.Science advances · 2024Article
- Applications of cell therapy in the treatment of virus-associated cancers.Nature reviews. Clinical oncology · 2024Review
- Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.The Journal of clinical investigation · 2024Article
- p53 at the crossroads of tumor immunity.Nature cancer · 2024Review
- Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens.bioRxiv : the preprint server for biology · 2024Article
- VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized therapy. A smaller subset of neoantigens includes epitopes that span recurrent mutation hotspots, translocations, or gene fusions in oncogenic drivers and tumor suppressors, as well as epitopes that arise from viral oncogenic proteins. Such antigens are likely to be shared across patients (public), uniformly expressed within a tumor, and required for cancer cell survival and fitness. Although a limited number of these public neoantigens are naturally immunogenic, recent studies affirm their clinical utility. In this review, we highlight efforts to target mutant KRAS, mutant p53, and epitopes derived from oncogenic viruses using T cells engineered with off-the-shelf T cell receptors. We also discuss the challenges and strategies to achieving more effective T cell therapies, particularly in the context of solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.